ENB Vs. Conventional Bronchoscopy With Fluoroscopy for Safe and Effective Biopsy of Pulmonary Lesions

Lung Neoplasms Clinical Trial

Official title:

A Prospective, Randomized, Multi-center, Superiority Clinical Study to Evaluate the Effectiveness and Safety of Bronchoscopic Lung Biopsy Under the Guide of CT Stereotactic Auxiliary Equipment and Accessories

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04447482
• Other study ID #: 202001131102-CT
• Status: Recruiting
• Phase: N/A
• Start date: July 10, 2020
• Est. completion date: September 30, 2021

Study information

• Verified date: March 2021
• Source: Shanghai Youhe Medical Technology Co., Ltd.
• Contact: Cathaly Hong
• Phone: 8613524168379
• Email: cathaly_hong[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate results for participants with lung lesions randomized to either 4D Electromagnetic Navigation Bronchoscopy (4D-ENB) versus Conventional Bronchoscopy with Fluoroscopy for diagnostic biopsy and detection of lung cancer.

Description:

The objective of this clinical trial is to evaluate the safety and efficacy results for two bronchoscopic biopsy techniques for sampling lung lesions: either image-guided electromagnetic navigation or conventional bronchoscopy with fluoroscopy. The diagnostic yield and adverse events of participants prospectively randomized to either arm will be evaluated. This is a prospective, randomized, multi-center study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 212
• Est. completion date: September 30, 2021
• Est. primary completion date: June 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subjects must meet all of the following criteria to be selected:

1. Be older than 18 (including 18) and younger than 75 (including 75);

2. The population with peripheral lung lesions detected in chest CT scanning and who require biopsy;

3. The subjects are willing to undergo bronchoscopy and meet the requirements for bronchoscopy;

4. The subjects or their guardians can understand the trial objective, volunteer to participate and sign the informed consent form.

Exclusion Criteria:

• Subjects will be excluded if they meet any of the following criteria:

1. The patient is participating in another drug or medical device clinical trial (drug clinical trial within 3 months or medical device clinical trial within 1 month);

2. Women of childbearing age who have positive pregnancy test result and lactating women;

3. Allergic to anesthetics;

4. Bronchoscopy contraindications, including: active massive hemoptysis; recent myocardial infarction or unstable angina pectoris; severe heart and lung dysfunction; severe hypertension and arrhythmia; uncorrectable bleeding tendency (such as severe coagulation disorders, uremia and severe pulmonary hypertension); severe superior vena cava obstruction syndrome; suspected aortic aneurysm; multiple pulmonary bullae; systemically extreme exhaustion.

5. Visible intraluminal lesions found during bronchoscopy;

6. Patients with severe lung diseases (including: severe bronchodilatation, severe emphysema, etc.) and patients determined to be unsuitable for the examination by the investigators;

7. Patients with a pacemaker or defibrillator;

8. Patients who cannot cooperate with the doctor to complete bronchoscopy, such as patients with mental and neurological diseases, mental retardation and mental disorders;

9. Patients to whom bronchoscopy and bronchoscopic sampling are not applicable to diagnose the lesions, or other patients determined to be unsuitable for this trial by the investigators.

Related Conditions & MeSH terms

• Lung Neoplasms
• Neoplasms
• Pulmonary Neoplasm

Intervention

Device:
• ENB with image-guided lung biopsy
Electromagnetic navigational bronchoscopy system with tip tracked instruments.

Procedure:
• Conventional Bronchoscopy guided by Fluoroscopy
Bronchoscopic lung biopsy with fluoroscopy.

Locations

Country	Name	City	State
China	The First Affiliated Hospital, Zhejiang University School of Medicine	Hanzhou	Zhejiang
China	Shanghai Changhai Hospital	Shanghai
China	Shanghai Chest Hospital	Shanghai
China	Shanghai East Hospital	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Youhe Medical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

References & Publications (2)

Flenaugh, E.L., & Mohammed, K.H.. Initial Experience Using 4D Electromagnetic Navigation Bronchoscopy System With Tip Tracked Instruments For Localization of Peripheral Lung Nodules. The Internet Journal of Pulmonary Medicine 18(1): 1-7, 2016.

Raval AA, Amir L. Community hospital experience using electromagnetic navigation bronchoscopy system integrating tidal volume computed tomography mapping. Lung Cancer Manag. 2016 Apr;5(1):9-19. doi: 10.2217/lmt-2015-0007. Epub 2016 Apr 8. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the diagnostic rate of lung biopsies between the treatment group and the control group.	Diagnostic rate is defined as the proportion of true positive and true negative.	6 months.
Secondary	Sampling success rate of the treatment group and the control group.	Sampling success rate means the proportion of lung nodules and abnormal lung tissues in all tissues sampled from bronchoscopic lung biopsy.	2 weeks.
Secondary	Navigation time (time to find the lesions) of the treatment group and the control group.	For this outcome, duration of procedure is defined as the time from the biopsy tool reaching the main carina (registration) to the biopsy tool reaching the lesion.	Duration of procedure, or up to 120 minutes.
Secondary	Total operation time of the treatment group and the control group.	For this outcome, duration of procedure is defined as the time from the bronchoscopy accessing the glottis for the first time to bronchoscopy exiting the glottis for the last time.	Duration of procedure, or up to 120 minutes.
Secondary	Navigation success rate of 4D-ENB and biopsy accessories.	Navigation success rate is defined as the proportion of the biopsy tools reaching the lung tissues. For this outcome, duration of procedure is defined as the time from the biopsy tool reaching the main carina (registration) to finishing the biopsy for the last time.	Duration of procedure, or up to 120 minutes.
Secondary	Device performance evaluation of CT Stereotactic Auxiliary Equipment and Accessories.	Device performance means the functions, reliability, safety and accessibility of the system. Performance will be evaluated by observing these characteristics during the procedure. For this outcome, duration of procedure is defined as the time from the biopsy tool reaching the main carina (registration) to finishing the biopsy for the last time.	Duration of procedure, or up to 120 minutes.